C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/85 (2006.01) A61K 47/48 (2006.01) A61K 48/00 (2006.01) C12N 5/10 (2006.01) C12N 15/52 (2006.01) C12N 15/86 (2006.01)
Patent
CA 2556790
The invention relates to the use of gene therapy in the treatment of aseptic loosening of orthopaedic prostheses and discloses methods of refixing such prostheses without open revision surgery. In particular, it provides prodrugs and adenoviral vectors comprising genes encoding prodrugs converting enzymes for simultaneous, separate or sequential use in the destruction of interface tissue allowing subsequent recementing of loose prostheses in a minimally invasive manner.
L'invention concerne la mise en oeuvre d'une thérapie génique dans le traitement d'un descellement aseptique d'une prothèse orthopédique. Elle concerne des procédés de réparation desdites prothèses sans réintervention avec effraction. On décrit en particulier des vecteurs adénoviraux et des promédicaments pouvant être utilisés simultanément, séparément ou séquentiellement dans la destruction du tissu interfaciel autorisant la reconsolidation subséquente d'une prothèse lâche avec effraction minimale.
Hoeben Robert C.
Huizinga Tom J. W.
Mountain Andrew
Nelissen Rob G. H. H.
Academisch Ziekenhuis Leiden
Innovata Limited
Innovata Plc
Long And Cameron
LandOfFree
Enzyme-prodrug therapy for prosthetic joint repair does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzyme-prodrug therapy for prosthetic joint repair, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme-prodrug therapy for prosthetic joint repair will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1761767